News about Clinical Trials

Imfinzi-Tarlatamab Combination Improves Overall Survival in Phase 3 ES-SCLC Trial

AstraZeneca and Amgen reported statistically significant improvements in overall and progression-free survival with Imfinzi plus tarlatamab versus Imfinzi alone in the Phase 3 DeLLphi-305 trial.

Clinical Trials | 10/09/2026 | By News Bureau

AstraZeneca Reports Positive Phase 3 Results for Tozorakimab in COPD

AstraZeneca’s Phase 3 OBERON and TITANIA trials showed that tozorakimab reduced moderate-to-severe COPD exacerbations across broad patient populations, including different blood eosinophil levels and smoking statuses.

Clinical Trials | 10/09/2026 | By News Bureau

Bayer Initiates Phase 2 Trial of Investigational GIRK4 Inhibitor for Atrial Fibrillation

Bayer has initiated a global Phase 2 trial of BAY 3670549, an investigational GIRK4 inhibitor being evaluated as a potential treatment for atrial fibrillation and rapid cardioversion.

Clinical Trials | 10/09/2026 | By News Bureau

Epicyt Pharma Reports Positive Phase 1/2a Results for BAFA in Post-Gastric Bypass Patients

Epicyt Pharma study shows statistically significant reduction in urinary calcium excretion and improvements in calcium homeostasis biomarkers, supporting planned Phase 2b development.

Clinical Trials | 09/09/2026 | By News Bureau

Ascletis Initiates US Phase 1 Study of Oral ASC36 for Obesity

Ascletis has initiated a US Phase 1 study of ASC36, an investigational oral amylin receptor peptide agonist developed using the company’s proprietary oral peptide delivery technology.

Clinical Trials | 09/09/2026 | By News Bureau

Bristol Myers Squibb Reports Positive Phase 2 Results for Arlo-cel in Relapsed/Refractory Multiple Myeloma

Bristol Myers Squibb’s arlo-cel demonstrated statistically significant and clinically meaningful responses in patients with quadruple-class exposed relapsed and refractory multiple myeloma.

Clinical Trials | 09/09/2026 | By News Bureau

Novartis Updates Phase 3 HARBOR Study of Del-desiran for DM1

Novartis reports del-desiran showed clinical activity in secondary endpoints and exploratory analyses in the phase 3 HARBOR study for DM1.

Clinical Trials | 09/09/2026 | By News Bureau

Rezubio Advances RZ-520 Into Phase 1 Trial Following FDA and NMPA Clearances

Rezubio has dosed the first cohort in a Phase 1 trial evaluating RZ-520, an investigational inhaled therapy for chronic respiratory diseases.

Clinical Trials | 08/09/2026 | By News Bureau

Suven Completes Phase 3 Enrollment of Masupirdine for Alzheimer's-Related Agitation

Suven Life Sciences completes enrollment in its global Phase 3 masupirdine trial, with 424 patients randomised to evaluate the therapy for agitation associated with Alzheimer’s dementia.

Clinical Trials | 05/09/2026 | By News Bureau

Tangram Therapeutics Advances TGM-312 into MASH Patient Cohorts in Phase 1/2 Trial

Tangram Therapeutics advances TGM-312 into MASH patient cohorts in its Phase 1/2 RESTORE-MASH trial while appointing Dr Sonya Montgomery as Chief Development Officer to drive its clinical pipeline.

Clinical Trials | 05/09/2026 | By News Bureau